High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
This article reviews the use of a selection of in vitro assays implemented at Novartis and intends to address exposure and safety in early drug discovery. The authors' own experience, based on a large number of 'real' drug discovery compounds, is described to reflect on what has worked, where improvement is needed and how to best use the data for decision making. Possible strategies are discussed, and guidelines are provided on how to organise assays, extract value and contribute knowledge from the data.
Faller
Bernard
B
Novartis Institutes for BioMedical Research, Basel, Switzerland. bernard.faller@novartis.com
Wang
Jianling
J
Zimmerlin
Alfred
A
Bell
Leslie
L
Hamon
Jacques
J
Whitebread
Steven
S
Azzaoui
Kamal
K
Bojanic
Dejan
D
Urban
Laszlo
L
D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D015195:Drug Design; D004345:Drug Industry / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D004364:Pharmaceutical Preparations / Q000737:chemistry / Q000378:metabolism*; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods*
D004364:Pharmaceutical Preparations; D003577:Cytochrome P-450 Enzyme System